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Article type      : Letter to the Editor 
 
Nasal gene expression changes with inhaled corticosteroid treatment in asthma 
 
To the Editor, 
Inhaled corticosteroids (ICS) improve asthma control in most, but not all patients(1,2). Currently, 
biomarkers that help clinicians to predict individual ICS responsiveness or monitor effects of therapy 
are limited. Gene expression profiling in bronchial tissue has revealed a signature related to ICS-
response(3), but access to this tissue is difficult. We recently showed that nasal gene expression can 
serve as a proxy to study effects of smoking in the lower airways(4), thereby providing a more 
accessible sampling alternative. In the current study, we aimed to investigate the effects of ICS-
treatment in nasal epithelium and confirmed results both in nasal brushes of patients after ICS-
withdrawal and in bronchial biopsies and air-liquid-interface (ALI) cultures after corticosteroid-
treatment. 
 
Data were collected from participants of two asthma studies on ICS-treatment: OLiVIA (n=39, 2-
week HFA-beclomethasone 200µg b.i.d.(5) and NZRHS (n=28, 12-week budesonide 400µg b.i.d(6)). 
Detailed information is available in the online supplement. In both studies, nasal brushes were 
obtained at baseline and after ICS treatment(7). A subpopulation of OLiVIA used ICS prior to the 
study and therefore had to withdraw their ICS 4-6 weeks. In this subpopulation, an additional nasal 
brush was taken before ICS withdrawal (Figure E1). In NZRHS, all participants had not used ICS for 
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microarray-based profiling (Affymetrix HuGene 1.0) in NZRHS. We used R-package limma 
(v3.30.13) to assess ICS-induced gene expression changes in nasal epithelium in OLiVIA and 
NZRHS and performed a meta-analysis to identify which genes are universally changed by ICS in 
both studies. P-values were adjusted for multiple testing using Benjamini-Hochberg procedure(8). 
Next, we compared results with nasal gene expression changes after withdrawal of ICS in OLiVIA 
using Gene Set Enrichment Analysis (GSEA, v3.0(9)). Additionally, we compared ICS-induced 
changes in gene expression from nasal samples with two independent asthma datasets of bronchial 
biopsies using GSEA (dataset 1: n= 12, 8-week budesonide 180µg b.i.d.; dataset 2: n= 20, 1-week 
fluticasone 500µg b.i.d.). Finally, we compared our findings with results of corticosteroid-induced 
changes in gene expression in ALI cultures of primary human bronchial epithelial cells (Table E1). 
 
In OLiVIA, mean age was 44 years (± standard deviation [SD] 13), 20 (51%) subjects were current-
smokers, 19 (49%) ex-smokers; mean FEV1 was 84 (±SD 14) %predicted. In NZRHS, mean age was 
45 years (±SD 12), 2 (7%) subjects were current-smokers, 10 (36%) ex-smokers and 16 (57%) never-
smokers; mean FEV1 was 88 (±SD 14) %predicted (Table E2). We identified 135 genes that 
significantly changed in expression with ICS treatment in our meta-analysis, 79 being up- and 56 
downregulated (FDR meta-analysis 0.05, nominal p<0.05 in both studies; Figure 1; Table E3). 
Unsupervised clustering of subjects was performed and showed clustering of NZRHS and OLiVIA-
subjects, but no clear clustering based on atopy-status, gender or clinical improvement after ICS 
treatment (responder/non-responder) (Figure E2). Genes downregulated after ICS treatment (n=56) 
were significantly enriched among genes upregulated after ICS withdrawal (Figure 2A). Genes 
upregulated after ICS treatment (n=79) were not significantly enriched among genes downregulated 
after ICS withdrawal (Figure 2B). When comparing our findings in nasal epithelium to those of the 
two independent studies using bronchial biopsies, GSEA showed that genes upregulated with ICS 
treatment in nasal epithelium were significantly enriched among genes upregulated with ICS 
treatment in bronchial biopsies (Figures 2C and 2E). Furthermore, genes downregulated after ICS 
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treatment in bronchial biopsies in both datasets (Figures 2D and 2F). Next, we compared results with 
corticosteroid-induced gene expression changes in ALI cultures (Table E4). GSEA analysis showed 
that genes upregulated with ICS treatment in nasal epithelium significantly overlap with upregulated 
genes in ALI cultures (Figure 2G). For downregulated genes, there was no significant overlap 
between downregulated genes in nasal epithelium and downregulated genes in ALI cultures (Figure 
2H). Gene ontology analysis with g-profiler(10), using the 135 ICS-induced genes as input, revealed 
pathways involved in death-domain signaling (Table E5). 
 
Together our results show that nasal brushes are suitable to study gene expression changes induced by 
ICS in asthma patients. We identified 135 genes that significantly change in expression after ICS 
treatment. Confirming the robustness of our findings, genes downregulated after ICS treatment were 
commonly upregulated after ICS withdrawal. In addition, ICS-induced gene expression changes in 
nasal epithelium considerably overlapped with ICS-induced gene expression changes in bronchial 
biopsies in 2 independent asthma cohorts.  
 
Among the top-10 upregulated genes were FKPB5 and CD163. The protein coded by FKBP5 is 
known to be upregulated by corticosteroids and functions as an inhibitor of the glucocorticosteroid 
receptor, thus playing a role in corticosteroid sensitivity(11). Studies investigating nasal and bronchial 
epithelium confirm our finding that FKBP5 is upregulated in response to corticosteroids in healthy 
participants(12), and those with asthma(3,13,14) and COPD(15). CD163 is a hemoglobin scavenger 
receptor exclusively expressed on monocytes and macrophages, and is a marker of alternatively 
activated M2 macrophages (16).  M2 macrophages are involved in allergic inflammation, wound 
healing and downregulation of inflammation by releasing the anti-inflammatory cytokine IL-10(17). 
Among the top-10 downregulated genes was TRADD. The protein coded by TRADD, Tumor Necrosis 
Factor (TNF) Receptor Type 1 Associated Death Domain Protein, is an essential member of the TNF-
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Corticosteroids are well known to suppress NFκB-signaling. Therefore, we hypothesize that one of 
the mechanisms by which corticosteroids inhibit NFκB-activation, is by inhibiting TRADD 
expression. 
 
The overlap between nasal and bronchial gene expression found in the current study is in line with 
two recent studies from our group, in which we showed strong resemblance between the nasal and 
bronchial gene expression profiles associated with COPD(7) and smoking(4). This overlap may be 
explained by multiple factors: 1) It could be speculated that ICS are inhaled through the mouth but 
exhaled through the nose, which induces direct exposure of the nasal epithelium to corticosteroids, 2) 
epithelial cells may communicate with each other through excretion of cytokines and other mediating 
molecules, leading to a similar gene expression profile throughout the airways. Additionally, 
validation of our findings in ALI cultures showed substantial overlap between ICS-induced 
upregulated genes in nasal brushes and upregulated genes in corticosteroid-treated ALIs. ALIs solely 
contain epithelial cells and no other cell types such as fibroblasts or inflammatory cells as can be 
present in nasal brushes. Therefore, we provide suggestive evidence that, for a subset of genes, 
expression changes in nasal brushes truly reflect expression changes of epithelial cells and not merely 
reflect a change in inflammatory cell type composition induced by corticosteroids. A strength of our 
study is the comparison of changes in nasal gene expression with ICS treatment and ICS withdrawal, 
as well as the comparison of our findings with corticosteroid-induced bronchial gene expression 
changes. Limitations of the study are the difference in smoking behavior and ICS-treatment duration 
between OLiVIA and NZRHS.  As a consequence, we might have missed genes that are affected by 
ICS in non-smokers only, or genes that change after a longer treatment period.  
In summary, we show that nasal gene expression is dynamic, changes with ICS treatment in asthma 
patients and can be used as a proxy for the lower airways to investigate ICS-induced gene expression 
changes. This opens avenues for future applications of nasal gene expression, such as prediction of 
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Figure 1. Delta heatmap showing the change in expression of 135 differential expressed genes in 
nasal brushes after ICS treatment. Patients are shown in columns and genes are shown in rows. A 
blue rectangle reflects downregulation of a gene after ICS treatment in a subject while a red rectangle 
reflects upregulation of a gene after ICS treatment in a subject. 
 
Figure 2. Gene Set Enrichment Analyses. The colored bar represents ranked t values of the 
association of each gene with change in gene expression after ICS treatment: red represents positive 
associations while blue represents negative associations. Black lines each represent a differential 
expressed gene after ICS treatment identified in the meta-analysis. The height of the black lines 
reflects the running enrichment scores of the GSEA. 
A) Genes downregulated in nasal brushes after ICS treatment are significantly enriched among genes 
upregulated after withdrawal of ICS (FDR=0.03) 
B) Genes upregulated in nasal brushes after ICS treatment are not significantly enriched among genes 
downregulated after withdrawal of ICS (FDR=0.69) 
C) and E) Genes upregulated in nasal brushes after ICS treatment are significantly enriched among 
genes upregulated in bronchial biopsies of asthma patients after ICS treatment (both FDR<0.01)  
D) and F) Genes downregulated in nasal brushes after ICS treatment are significantly enriched among 
genes downregulated in bronchial biopsies of asthma patients after ICS treatment (both FDR<0.01) 
G) Genes upregulated in nasal brushes after ICS treatment are significantly enriched among genes 
upregulated in corticosteroid-treated ALI cultures (FDR<0.01) 
H) Genes downregulated in nasal brushes after ICS treatment are not significantly enriched among 
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